Sirolimus In Dermatology: A Guide To Topical And Oral Use

Sirolimus, also known as rapamycin, is a macrolide compound with potent immunosuppressive and antiproliferative properties. Initially discovered as an antifungal agent from Streptomyces hygroscopicus on Easter Island (Rapa Nui), it has evolved into a key therapeutic in transplantation, oncology, and dermatology. In skin medicine, sirolimus inhibits the mechanistic target of rapamycin (mTOR), a serine/threonine kinase central to cell growth, proliferation, metabolism, and survival pathways.

What is sirolimus?

Sirolimus binds to FK-binding protein 12 (FKBP12), forming a complex that allosterically inhibits mTOR complex 1 (mTORC1). This blocks downstream signaling, including S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1), suppressing protein synthesis, cell cycle progression, and angiogenesis. Unlike calcineurin inhibitors (e.g., tacrolimus), sirolimus spares T-cell activation while preventing clonal expansion, reducing rejection without broad immunosuppression.

Approved formulations include oral tablets (Rapamune®), intravenous solutions, and topical gels (Hyftor® 0.2% for facial angiofibromas). Off-label topical compounded versions (0.1–1%) treat vascular anomalies and proliferations.

Who gets sirolimus in dermatology?

Sirolimus targets mTOR-hyperactive disorders:

• Tuberous sclerosis complex (TSC): Facial angiofibromas (adenoma sebaceum), shagreen patches, ungual fibromas.
• Vascular malformations: Tufted angiomas, kaposiform hemangioendotheliomas, lymphatic anomalies.
• Proliferative disorders: Keratinocyte carcinomas, epithelial nevi, psoriasis.
• Immunobullous diseases: Pemphigus vulgaris (refractory cases).
• Post-transplant skin cancers: Squamous cell carcinomas in organ recipients.

TSC affects 1 in 6,000 births; facial angiofibromas occur in 70–80% of patients, causing disfigurement.

What is the mechanism of action of sirolimus?

mTOR integrates growth signals (amino acids, energy, growth factors). TSC1/TSC2 loss (hamartin/tuberin) derepresses mTORC1, driving hamartomas. Sirolimus restores feedback inhibition:

• Inhibits angiogenesis (VEGF reduction).
• Induces autophagy (cell cleanup).
• Suppresses keratinocyte/fibroblast proliferation.

Topical sirolimus achieves high skin concentrations with minimal systemic absorption (trough levels <1 ng/mL), ideal for localized disease.

How is topical sirolimus used?

Approved (Hyftor® 0.2% gel): For TSC facial angiofibromas (ages ≥6 years).

• Apply pea-sized amount once daily to clean, dry face.
• Avoid eyes, mouth, mucosa.
• Do not occlude unless directed.

Compounded topical (0.1–1% cream/ointment/gel/oil):

• Thin layer 1–2x daily to lesions.
• Vehicle: Aqueous cream, VersaBase®, Lipoderm® for penetration.
• Duration: 3–12 months; reassess response.

Wash hands pre/post-application. Sun protection essential (SPF 50+).

Dosing table

Systemic sirolimus in dermatology

Oral sirolimus (1–5 mg/day; target trough 5–15 ng/mL) for extensive TSC, lymphatic malformations, or post-transplant skin cancer prophylaxis. Monitor lipids, CBC, renal function monthly. Combination with low-dose everolimus under study.

Response to treatment

Topical: 50–75% lesion size reduction in 3–6 months for angiofibromas (FDA pivotal trial: Hyftor® superior to vehicle, p<0.0001). Vascular tumors shrink 30–70%; color fades. Maintenance: Taper to 2–3x/week.

• Success factors: Early intervention, adherence, combination laser (pulsed dye).
• Non-responders: Deep nodules, poor compliance.

What are the side effects of sirolimus?

Topical: Mild, local (37–40% irritation, dry skin; 17% itch; 7% acne). Systemic absorption rare (<5%).

Serious risks (mostly oral form):

• Cancer (lymphoma, skin SCC; use sunscreen).
• Infections (PML, zoster; avoid live vaccines).
• Interstitial lung disease (cough, dyspnea).
• Angioedema (ACEi interaction).
• Hyperlipidemia, infertility.

Dermatologic: Oral ulcers (50%+), acneiform rash (scalp/face/back), edema (47%), folliculitis (27%), xerosis. Grade 1–2; discontinue if severe.

Side effects table

Management of side effects

• Local irritation: Dilute concentration, emollients, short-contact (1–2h then wash).
• Acne: Topical retinoids, benzoyl peroxide.
• Ulcers: Triamcinolone paste, dose reduction.
• Edema: Elevate, low-salt diet.
• Infection: Culture, antibiotics; hold sirolimus.

Interactions and precautions

Drug interactions: CYP3A4 inhibitors (ketoconazole ↑ levels); inducers (rifampin ↓). Avoid grapefruit, St. John’s wort.

• No live vaccines.
• Pregnancy Category C: Teratogenic (contraception mandatory).
• Hyperlipidemia: Statins.

Monitor trough levels (oral), LFTs, lipids q3months.

Frequently asked questions

What conditions does topical sirolimus treat?

Approved for TSC facial angiofibromas; off-label for vascular malformations, nevi, post-transplant skin cancers.

Is topical sirolimus safe long-term?

Yes, minimal systemic absorption; monitor for local effects. Sunscreen prevents skin cancer risk.

Can I use sirolimus while breastfeeding?

Avoid; unknown excretion in milk. Pump/discard during therapy.

How quickly does sirolimus work on angiofibromas?

Visible improvement in 2–4 weeks; peak response 3–6 months.

What if topical sirolimus irritates my skin?

Reduce frequency, dilute, or switch vehicle. Consult dermatologist.

Similar Articles

Alarming Rise in Self-Harm in Young People

Alarming Rise in Self-Harm in Young People

Skin Signs Of Non-Accidental Injury: Expert Guide For Clinicians

Lichen Simplex Of The Scrotum: Diagnosis And Treatment

Labial Adhesion In Prepubertal Girls: What Parents Need To Know

Thrush In Men: 5 Signs, Causes, And Treatment Options

Author

medha deb

 

Medha Deb is an editor with a master's degree in Applied Linguistics from the University of Hyderabad. She believes that her qualification has helped her develop a deep understanding of language and its application in various contexts.

Read full bio of medha deb